PRNewsWire
13 Jun 2026, 00:30 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Simcere Pharmaceutical Group Limited entered into a research collaboration with Stanford Medicine to develop innovative treatments for idiopathic pulmonary fibrosis (IPF). — Partnering with a world-class institution like Stanford increases the probability of technical success for a high-unmet-need therapeutic area.
+0.40Simcere will acquire a license to the target molecule and 100% of the resulting product's global rights upon the successful completion of the research. — Full global ownership of a successful candidate provides a significant potential revenue stream and asset value growth.
+0.30Which stocks this story touches
The company entered into a strategic research collaboration with Stanford Medicine to develop innovative treatments for idiopathic pulmonary fibrosis and secure global rights to a new molecule.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
